Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Normal saline, Control · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Normal saline (1000 mL) | OTHER | - |
| Control | OTHER | - |
Normal saline,Control is used for the treatment of migraine headache. It is being studied as an intravenous fluid therapy for patients presenting to the emergency department with migraine headache. The drug is currently in clinical development for this indication.
Normal saline,Control is being developed by The Cooper Companies, Inc., which trades under the ticker COO. The company is conducting clinical research on this product for the treatment of migraine headache.
Normal saline,Control is in Phase 3 clinical development for migraine headache. A clinical trial with the identifier NCT02933060 has been completed, which was listed as a Phase 2/Phase 3 study. The drug remains investigational and has not been approved by regulatory authorities.
Normal saline,Control has one completed clinical trial, NCT02933060, titled "Intravenous Fluid Therapy for the Treatment of Emergency Department Patients With Migraine Headache." This study enrolled 50 participants and was conducted to evaluate the treatment for migraine headache.
Normal saline,Control is a name used in clinical research to refer to the investigational product being studied for migraine headache. It is being evaluated as an intravenous fluid therapy. The product is developed by The Cooper Companies, Inc. and is currently in Phase 3 development.